Created with Highcharts 11.1.0Jul '24Oct '24Jan '25Apr '252.502.77

Profile

Edit
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
URL https://www.adctherapeutics.com
Investor Relations URL https://ir.adctherapeutics.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 06, 2025 (est.)
Last Earnings Release May. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
URL https://www.adctherapeutics.com
Investor Relations URL https://ir.adctherapeutics.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 06, 2025 (est.)
Last Earnings Release May. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows